Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners
Linkedbio Partnering: Linkedbio Analysis:
Lingmed Newsletter Oct 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative Oral Epilepsy drug from EU
Lingmed asset recommendation 2：U.S. Malignant Pleural Effusion Project
Lingmed monthly webinar Nov 2024: Analysis of drug targets and key pharmaceutical companies in pain therapeutic area
The Sep 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Sep 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.383U.S. Malignant Pleural Effusion Treatment Project Seeking Global Collaboration – LMP2711
Epidemiology of Malignant Pleural Effusion (MPE)
Treatment of Malignant Pleural Effusion in China
Lingmed Project Recommendation - Malignant Mesothelioma/Pleural Effusion Project
Lingmed asset recommendation No.381European Innovative Oral Epilepsy Medication Seeking Partnership in China – LMP2719
Epidemiology of Focal Epilepsy
Treatment of Focal Epilepsy in China
Lingmed Project Recommendation - Focal Epilepsy Project
Lingmed Newsletter Sep 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：High potential neuropathic pain program from EU
Lingmed asset recommendation 2：First in class androgenetic hair loss program
Lingmed monthly webinar Nov 2024: Analysis of drug targets and key pharmaceutical companies in pain therapeutic area
The Aug 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Aug 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.380European high-potential FLT3 inhibitor drug program seeks global collaboration - LMP1249
Epidemiology of neuropathic headache in the world & China
Neuropathic pain treatment in China
The issue of Lingmai’s Program Recommendations - Neuropathic Pain Program
Lingmed asset recommendation No.378First New Drug for Androgenetic Hair Loss Program – LMP1828
Global & Chinese Androgenetic Alopecia Epidemiology
Global Ranking of Androgenetic Alopecia Drugs
Treatment of androgenetic alopecia in China
This issue of Lingmai project recommendation - androgenetic alopecia project
Lingmed Newsletter Aug 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Solid Tumor ADC Program
Lingmed asset recommendation 2：Overseas Allergic Disease Program
Lingmed monthly webinar Sep 2024: Application of nano-antibodies in autoimmune diseases, are you ready?
The Jul 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Jul 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.377Overseas Allergic Disease Program Seeks Global Collaboration – LMP1957
Item No.: LMP1957; LMP2662 Technology Platform
Project description
Project stage
Indication
Project requirements: LMP1957 looking for partner in Japan; LMP2662 technology platform global collaboration open for negotiation
Lingmed asset recommendation No.376Solid Tumor ADC Program Seeks Chinese Collaboration – LMP1983
Item number: LMP1983 linker; LMP1984
Project description: anti-B7-H3 dual oncolytic ADCs
Project stage: Preclinical
Indication: solid tumors
Project requirements: ADC platform technology and incubation projects looking for global collaboration, multiple collaborations negotiable
Lingmed Newsletter July 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative psoriasis program from EU
Lingmed asset recommendation 2：Innovative antibiotic resistance program from EU
Lingmed monthly webinar Sep 2024: Breakthrough and Innovation—Application of Regenerative Medicine in Neurological Diseases
The Jun 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Jun 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.373Innovative Antibiotic Resistance Program in Europe Seeks Global Collaboration – LMP2661
Item No.: LMP2661
Project description: Metallo-β-lactamase inhibitor；β-lactamase inhibitor
Development Status: Phase 1 approved，planning to start in September，2024
Target Indications: Complicated Gram-negative bacterial infections，suitable for patients with complicated urinary tract, intra-abdominal, pulmonary, and bloodstream infections
Licensing Opportunities: LMC5001504 is looking for an opportunity to out-license LMP 2661 in Greater China.
Lingmed asset recommendation No.372European psoriasis nanobody drug program seeks global collaboration – LMP2663
Epidemiology of psoriasis in the world & China
Treatment of psoriasis in China
This issue of Lingmed's Program Recommendation - Mild to Moderate Psoriasis Nano Antibody Program
Lingmed Newsletter June 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Neurodegenerative Disease Program
Lingmed asset recommendation 2：U.S. HER2+ Gastric/Breast Cancer Bispecific Antibody Program
Lingmed monthly webinar Jul 2024: Breakthroughs & progress of antiepileptic drugs
The May 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The May 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.370U.S. HER2+ Gastric/Breast Cancer Dual Antibody Program Seeks Chinese Collaboration – LMP2658
Global & Chinese Gastric Cancer Epidemiology
Treatment of HER2+ gastric cancer in China
This issue of Lingmed’s Program Recommendation - HER2+ Gastric/Breast Cancer Program
Lingmed asset recommendation No.369Neurodegenerative Disease Program seeks global partnering – LMP1888
Global & Chinese Epidemiology of Alzheimer's Disease
Treatment of Alzheimer's disease in China
This issue of Lingmed’s Program Recommendation - Neurodegenerative Disease Program
Lingmed Newsletter May 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Novel MBL inhibitors reviving resistant antibiotics
Lingmed asset recommendation 2：Innovative drug delivery technology program from North American
Lingmed asset recommendation 3：IBD program with innovative target from EU
Lingmed monthly webinar Jun 2024: Breakthrough in the treatment of rare tumor malignant pleural mesothelioma
The Apr 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Apr 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.367North American Innovative Drug Delivery Technology Program seeks global partnering – LMP2660
Epidemiology of OA and EoE globally & in China
Treatment of OA and EoE in China
This issue of Lingmed’s project recommendation - OA and EoE project
Lingmed asset recommendation No.366Early Innovative Breakthroughs in New Targets for Chronic Inflammatory Bowel Disease IBD Seek Chinese Collaboration – LMP1951
Global & Chinese Inflammatory Bowel Disease Epidemiology
Treatment of inflammatory bowel disease in China
This issue of Lingmed's program recommendation - Inflammatory Bowel Disease program
Lingmed Newsletter April 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Rheumatoid Arthritis Program from EU
Lingmed asset recommendation 2：Rare chronic autoimmune disease program from North America
Lingmed monthly webinar May 2024: The past, present and future of antibiotic development
The Mar 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Mar 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.364North America rare chronic autoimmune disease program seeks global partnering – LMP2001
Global & Chinese System Sclerosis and FSGS Epidemiology
Treatment of System Sclerosis and FSGS in China
This issue of Lingmed's Project Recommendation - Dual Adaptation Rare Disease Project
Lingmed asset recommendation No.362European Rheumatoid Arthritis Program Seeks Global Collaboration – LMP1898
Global & Chinese Rheumatoid Arthritis Epidemiology
Global Rheumatoid Arthritis Drug Rankings
Treatment of rheumatoid arthritis in China
This issue of Lingmed’s program recommendation - rheumatoid arthritis program
Lingmed Newsletter March 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Immune checkpoint blockade therapy Adjuvant Program from EU
Lingmed asset recommendation 2：Peripheral T-Cell Lymphoma Program
Lingmed monthly webinar Apr 2024: Research and progress of CAR-T cell therapy for solid tumors [Register]
The Feb 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Feb 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.361Peripheral T-Cell Lymphoma Program Seeks Global Collaboration – LMP1997
Global & Chinese Epidemiology of Peripheral T-Cell Lymphoma
Treatment of peripheral T-cell lymphoma in China
This issue of Lingmed's Program Recommendation - Peripheral T-cell Lymphoma Program
Lingmed Newsletter Feb 2024In this month summary, Lingmed recommends
Lingmed asset recommendation：Respiratory diseases project from EU
Lingmed monthly webinar March 2024: Breakthrough & progress of novel targeted lipid-lowering drugs
The Jan 2024 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Jan 2024 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Jan 2024In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Acute ischemic stroke and post-stroke depression project with dual MoAs
Lingmed asset recommendation 2：Innovative Osteoarthritis project
Lingmed monthly webinar Feb 2024: Breakthrough & progress of novel targeted lipid-lowering drugs
The Dec 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Dec 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Dec 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：First-In-Class hypertrophic Scar & Keloids project
Lingmed asset recommendation 2：Oncology nuclear drug with innovative target
Lingmed monthly webinar Jan 2024: New blue ocean market—Novel weight loss drugs
The Nov 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Nov 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Nov 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative type 2 diabetes sustained-release project from US
Lingmed asset recommendation 2：Migraine Inhalation Project from EU
The Oct 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Oct 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Oct 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative oral preparation project for Age-related Macular Degeneration
Lingmed asset recommendation 2：Innovative respiratory disease project from EU
Lingmed monthly webinar Nov 2023: Research progress in the pathogenesis and treatment of depression
The Sep 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Sep 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed Newsletter Sep 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Long-acting Pulmonary Arterial Hypertension Program from EU
Lingmed asset recommendation 2：Long-acting Preloaded Prostate Cancer program from EU
Lingmed monthly webinar Oct 2023: Breakthrough & Progress of Non-small cell lung cancer drug Register
The Aug 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Aug 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.344European Long-Term Pulmonary Arterial Hypertension Program seeks global partnering
Global and China Pulmonary Hypertension Epidemiology
Global Pulmonary Arterial Hypertension Drug Ranking
Treatment of Pulmonary Arterial Hypertension in China
Lingmed innovative asset recommendation –Pulmonary Arterial Hypertension
Lingmed asset recommendation No.343European Long-acting Preloaded Prostate Cancer program seeks global partnering - LMP1855
Global and China Prostate Cancer Epidemiology
Global Prostate Cancer Drug Ranking
Treatment of Prostate Cancer in China
Lingmed innovative asset recommendation – Prostate Cancer program
Lingmed Newsletter Aug 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Spot light on dermatology innovation - Cure for chronic Spontaneous Urticaria
Lingmed asset recommendation 2：Innovative Chronic Kidney Disease program
Lingmed monthly webinar Sep 2023: Breakthrough & Progress of Non-small cell lung cancer drug Register
The 12th Pharma - Biotech Product and Company Valuation Register
The July 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The July 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.341Innovative Chronic Kidney Disease program seeks a global partner
Global and China Chronic Kidney Disease Epidemiology
Global Chronic Kidney Disease Drug Ranking
Treatment of Chronic Kidney Disease in China
Lingmed innovative asset recommendation – Chronic Kidney Disease project
Lingmed asset recommendation No.340Spot light on dermatology innovation - Cure for chronic Spontaneous Urticaria?
Global and Chinese Epidemiology of Chronic Spontaneous Urticaria
Global and Chinese Urticaria Drug Ranking
Treatment of Chronic Spontaneous Urticaria in China
Lingmed innovative asset recommendation – Chronic Spontaneous Urticaria Program
Lingmed asset recommendation No.338China's rising stars of innovation - portable inhalation device for pulmonary hypertension - Patent global licensing opportunity LMP1853
Medical NO gas therapy has wide application potential
Integrating more than 60 patents to establish a solid NO generation molecular technology platform
Potential indications and product forms
Portable nitric oxide inhalation therapy device
Product features
The main uses of the LMP1853 portable inhaled nitric oxide therapy device
Cooperation models
Lingmed Newsletter July 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Innovative U.S. Anesthesia Reversal Agent program
Lingmed asset recommendation 2：Oversea topical skin disease innovation
Lingmed monthly webinar Aug 2023: Development progress of new drug development for skin diseases Register
The 12th Pharma - Biotech Product and Company Valuation Register
The Jun 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Jun 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.336Oversea topical skin disease innovations
Global and Chinese Acne Epidemiology
Global and Chinese Acne Drug List
Chinese acne treatment
Lingmed innovative asset recommendation – Skin Disease Program
Lingmed asset recommendation No.336Innovative U.S. Anesthesia Reversal Agent program seeks partnering into China market
Global Epidemiology of Delayed Awakening from Anesthesia
Global & Chinese Delayed Awakening from Anesthesia Drug Ranking
Chinese Guidelines for Treatment of Delayed Awakening from Anesthesia
Lingmed innovative asset recommendation – Anesthesia Reversal Agent Program
Lingmed Newsletter June 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：New breakthrough in innovative target for rare blood diseases
Lingmed asset recommendation 2：Overseas Primary Sclerosing Cholangitis program
Lingmed monthly webinar Jul 2023: Chronic Pain Market Development Potential and Market Size Register
The 12th Pharma - Biotech Product and Company Valuation Register
The May 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The May 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.334Overseas primary sclerosing cholangitis program seeks partnering into China market
Global and Chinese PSC Epidemiology
Global & Chinese PSC Drug Ranking
Chinese guidelines for diagnosis and treatment of PSC
Lingmed innovative asset recommendation – Primary Sclerosing Cholangitis Program
Lingmed asset recommendation No.333New breakthrough in innovative target for rare blood diseases - LMP1421
Global PNH Epidemiology
Global & Chinese PNH Drug Ranking
Chinese guidelines for diagnosis and treatment of PNH
Lingmed innovative asset recommendation – PHN Program
Lingmed Newsletter May 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Overseas First-Line Therapy Program for Pancreatic Cancer
Lingmed asset recommendation 2：U.S. Innovative Oncology Program
Lingmed monthly webinar Jun 2023: Prospects for drug development of heterologous antibodies Register
The Apr 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Apr 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.331Oncology innovation from US biotech seeks partnering into China market
Global epidemiology of AML/ALL, DLBCL, MM and other tumors
Global & Chinese AML/ALL Drug Ranking
China AML/ALL diagnosis and treatment guidelines
Lingmed innovative asset recommendation – Multi-tumor Indication Program
Lingmed asset recommendation No.328Overseas First-Line Therapy Program for Pancreatic Cancer Seeks Chinese Collaboration
Global & Chinese Pancreatic Cancer Epidemiology
Global Pancreatic Cancer Drug Ranking
China Pancreatic Cancer Treatment Guidelines (2022)
Lingmed innovative asset recommendation – Pancreatic Cancer and Pulmonary Fibrosis Program
Lingmed Newsletter April 2023In this month summary, Lingmed recommends
Lingmed asset recommendation 1：Phase III Tenosynovial Giant Cell Tumor Program from EU
Lingmed asset recommendation 2：U.S. Innovative Respiratory Infection Program
Lingmed monthly webinar May 2023: R&D pattern analysis of novel drug delivery systems Register
The Mar 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
The Mar 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team
Lingmed asset recommendation No.329U.S. Innovative Respiratory Infection Program Seeks Chinese Collaboration
Company Profile
Respiratory Infection Program LMP1857 Introduction
LMP1857 potential applications
LMP1857 patent status
LMP1857 Cooperation Opportunities
Lingmed asset recommendation No.327European Phase III Tenosynovial Giant Cell Tumor Program Seeks Chinese Collaboration
Global & Chinese Epidemiology of Tenosynovial Giant Cell Tumor
Global Tenosynovial Giant Cell Tumor Drug Ranking
Guidelines for Diagnosis and Treatment of Giant Cell Tumor of the Tendon Sheath in China
Lingmed innovative asset recommendation – Tenosynovial giant cell tumor program
If you are interested in Lingmed historical achieved reports, please click here
Confirm your details on form below to download this report
